Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(2):108-109; doi:10.1093/jnci/djk040
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schmidt, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

THE NEED FOR SPEED

Adaptive Design May Hasten Clinical Trials

Charlie Schmidt

The first 10% of the full text of this article appears below.

It's no secret that drug development can be time-consuming, costly, and prone to failure. That's especially true for new cancer drugs, which succeed in clinical trials only about 5% of the time—roughly half the success rate for all new drugs combined, according to a report in the August 2004 issue of Nature Reviews Drug Development. Despite those dismal odds, the cancer drug business is booming: In September 2006, more than 600 oncology drugs were in clinical development; a 10% increase since 2001, according to Kalorama Information, the publishing division of MarketResearch.com.

Those rising numbers have fueled pressure to speed the clinical trials that evaluate new cancer drugs. Both the U.S. Food and Drug Administration and the National Cancer Institute are now investigating adaptive designs that may accomplish . . . [Full Text of this Article]

Adaptive Designs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 aacredbookHome page
J J. Lee
Adaptive Designs for Efficacy and Toxicity Endpoints in Early Drug Development
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 631 - 636.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni
Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs
J. Clin. Oncol., August 10, 2007; 25(23): 3389 - 3391.
[Full Text] [PDF]